RetinalGenix Technologies filings document public-company reporting status, financial-statement timing, and governance changes for a developmental-stage company focused on retinal imaging, genetic testing, and pharmacogenetic mapping. The record includes a Form 12b-25 notification related to the timing of its annual report and an 8-K reporting an executive officer resignation, with disclosures centered on reporting obligations, financial statement finalization, and management structure.
RetinalGenix Technologies Inc. (RTGN) reported no revenue and a third-quarter net loss of $433,025, compared with $568,791 a year earlier. For the nine months ended September 30, 2026, net loss was $1,330,911, and operating cash use was $328,368.
At September 30, 2026, RTGN had $5 in cash, liabilities of $2,032,543 and an accumulated deficit of $19,189,528. The company said its cash was expected to fund operations for only a few days and that it lacked resources through November 2026 without future capital raising, raising substantial doubt about its ability to continue as a going concern. RTGN estimates it needs approximately $7 million in additional operating capital.
In August, RTGN issued 442,670 shares to Sanovas to offset $996,007 due for expenses paid on its behalf. A shareholder’s $50,000 note matured unpaid on October 1, 2026; RTGN said it was in default, and the lender had informally agreed to extend the maturity date. Management reported ineffective controls due to a material weakness from a lack of segregation of duties.
RetinalGenix Technologies Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to operate as a pre-commercial ophthalmic R&D company. Net loss was $307,397 for the quarter and $897,886 for the first half, narrower than the prior-year periods, driven mainly by lower general and administrative and stock-based compensation expenses, partially offset by higher research and development spending on the RetinalCam project.
At June 30, 2026, cash was $27,232 against total liabilities of $2,672,914 and an accumulated deficit of $18,756,503, leaving a stockholders’ deficit of $2,640,699. The company discloses substantial doubt about its ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance product development, genetic testing, and its AI database. Operations remain heavily supported by related party Sanovas, to which $996,007 was owed at June 30, 2026; this balance was subsequently exchanged for 442,670 common shares.
The company sold 88,889 shares at $2.25 per share during the period, maintains significant potential dilution through 780,000 stock options, 1,950,000 warrants, and a 28,014,540-share pre-funded warrant, and reports a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. reported that Liebman Hymowitz, LLP resigned as its independent registered public accounting firm, effective July 13, 2026. Liebman Hymowitz’s audit reports on the consolidated financial statements for the years ended December 31, 2025 and December 31, 2024 were unqualified but included an explanatory paragraph describing substantial doubt about the company’s ability to continue as a going concern. The company states there were no disagreements with Liebman Hymowitz on accounting principles, financial statement disclosure, or auditing scope or procedures, and no reportable events other than previously disclosed issues involving internal control over financial reporting and disclosure controls and procedures.
On July 15, 2026, RetinalGenix engaged Vilki & Co., Charted Accountants as its new independent registered public accounting firm for the year ending December 31, 2026. The company indicates it did not consult Vilki & Co. in advance on accounting principles, potential audit opinions, or any matters involving disagreements or reportable events. RetinalGenix has requested a letter from Liebman Hymowitz addressed to the SEC confirming its agreement with these disclosures, to be filed as Exhibit 16.1.
RetinalGenix Technologies Inc. shareholder Steven Bayern, for Bayern Capital LLC, reported a proposed sale of 181,900 common shares, with an approximate sale date of June 11, 2026.
The securities information records an acquisition of 4,214,000 shares from the company through warrant exercise on September 1, 2018. Bayern Capital LLC also reported selling 500 common shares on May 4, 2026, for gross proceeds of $1,685.90. RetinalGenix lists 18,843,628 common shares outstanding.
RetinalGenix Technologies Inc. reported another quarterly loss and severe liquidity pressure for the quarter ended March 31, 2026. The company generated no revenue and recorded a net loss of $590,489, similar to the prior year period, driven by $262,149 of general and administrative costs, $117,064 of research and development, and $210,016 of stock-based compensation.
Cash fell to just $180 at March 31, 2026 against total liabilities of $2,563,889 and an accumulated deficit of $18,449,106, leaving a significant stockholders’ deficit. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance its retinal imaging devices, DNA/GPS genetic testing platform, and related AI database toward commercialization. Operations remain heavily supported by related-party Sanovas, which is owed about $830,632. The filing also notes a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. files its annual report describing a development-stage ophthalmic business with no product revenue and recurring net losses. The company focuses on four pillars: genetic testing, retinal imaging, a patient information database, and repurposed pharmaceutical therapies for dry age-related macular degeneration and Alzheimer’s dementia.
Management plans initial genetic test sales and beta retinal imaging in 2026 and potential commercialization in 2027, but discloses substantial doubt about its ability to continue as a going concern. RetinalGenix estimates it needs about $7 million in additional funding and has recently raised smaller amounts through private stock placements.
RetinalGenix Technologies Inc. reported that its Chief Financial Officer, Michael Cory Zwerling, resigned from his position, effective immediately on March 22, 2026. The company did not provide additional details about the circumstances of his departure or plans for a successor in this report.